Therapeutic Area: Oncology

Primary germinal center-resident T follicular helper cells are a physiologically distinct subset of CXCR5 hi PD-1 hi T follicular helper cells

Yeh C, et al.
Immunity
August 2022
immuneAccess
Authors and Affiliates
Chen-Hao Yeh 1, Joel Finney 1, Takaharu Okada 2, Tomohiro Kurosaki 3, Garnett Kelsoe 4; 1 Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA. 2 Laboratory for Tissue Dynamics, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa 230-0045, Japan; Graduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa 230-0045, Japan. 3 Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan; Laboratory for Lymphocyte Differentiation, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa 230-0045, Japan. 4 Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery and Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: ghkelsoe@duke.edu.

Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

Schad SE, et al.
Journal of Experimental Medicine
August 2022
Authors and Affiliates
Sara E Schad 1,2, Andrew Chow 1,3, Levi Mangarin 1, Heng Pan 2,4, Jiajia Zhang 5,6, Nicholas Ceglia 7, Justina X Caushi 5,6, Nicole Malandro 1,2, Roberta Zappasodi 1,2, Mathieu Gigoux 1, Daniel Hirschhorn 1, Sadna Budhu 1, Masataka Amisaki 8, Monica Arniella 9, David Redmond 2, Jamie Chaft 3, Patrick M Forde 5,6, Justin F Gainor 10, Matthew D Hellmann 3, Vinod Balachandran 1,3,8,11, Sohrab Shah 7, Kellie N Smith 5,6, Drew Pardoll 5,6, Olivier Elemento 2,4, Jedd D Wolchok 1,2,3,12, Taha Merghoub 1,2,3,12; 1 Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, NY. 2 Weill Cornell Medical College, New York, NY. 3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 4 Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY. 5 John Hopkins University School of Medicine, Baltimore, MD. 6 Bloomberg-Kimmel Institute for Cancer Immunotherapy at John Hopkins, Baltimore, MD. 7 Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 8 Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY. 9 Broad Institute of MIT and Harvard, Cambridge, MA. 10 Department of Medicine, Massachusetts General Hospital, Boston, MA. 11 Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 12 Human Oncology Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition

Alvarez-Breckenridge C, et al.
Cancer Immunology Research
August 2022
Authors and Affiliates
Christopher Alvarez-Breckenridge #,1,2, Samuel C Markson #,3,4,5,6, Jackson H Stocking 7, Naema Nayyar 7, Matt Lastrapes 5,6,8, Matthew R Strickland 7,9, Albert E Kim 7,9, Magali de Sauvage 7, Ashish Dahal 7, Juliana M Larson 7, Joana L Mora 5,6,9, Andrew W Navia 10,11,12,13, Robert H Klein 7, Benjamin M Kuter 7, Corey M Gill 7, Mia Bertalan 7, Brian Shaw 7, Alexander Kaplan 7, Megha Subramanian 7, Aarushi Jain 7, Swaminathan Kumar 14, Husain Danish 15,16, Michael White 7, Osmaan Shahid 6, Kristen E Pauken 3,4, Brian C Miller 3,4,5,17, Dennie T Frederick 18, Christine Hebert 19, McKenzie Shaw 19, Maria Martinez-Lage 19, Matthew Frosch 20, Nancy Wang 7, Elizabeth Gerstner 9, Brian V Nahed 2, William T Curry 2, Bob Carter 2, Daniel P Cahill 2, Genevieve Marie Boland 18, Benjamin Izar 21,22, Michael A Davies 14, Arlene H Sharpe 3,4,5, Mario L Suvà 5,19, Ryan J Sullivan 7,9, Priscilla K Brastianos #,5,7,9, Scott L Carter #,5,6; 1 Departments of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2 Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts. 3 Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts. 4 Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts. 5 Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts. 6 Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts. 7 Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts. 8 Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9 Massachusetts General Hospital Cancer Center, Boston, Massachusetts. 10 Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts. 11 Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, Massachusetts. 12 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. 13 Ragon Institute, Harvard University, Massachusetts Institute of Technology, and Massachusetts General Hospital, Cambridge, Massachusetts. 14 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 15 Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York. 16 Weill Cornell Medical Center, New York, New York. 17 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 18 Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 19 Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 20 C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 21 Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York. 22 Columbia Center for Translational Immunology, New York, New York. # Contributed equally.

Sensory nerves impede the formation of tertiary lymphoid structures and development of protective anti-melanoma immune responses

Vats K, et al.
Cancer Immunology Research
August 2022
immuneAccess
Authors and Affiliates
Kavita Vats 1, Oleg Kruglov 2, Bikram Sahoo 3, Vishal Soman 1, Jiying Zhang 4, Galina V Shurin 5, Uma R Chandran 6, Pavel Skums 7, Michael R Shurin 5, Alex Zelikovsky 8, Walter J Storkus 6, Yuri L Bunimovich 6; 1 University of Pittsburgh, United States. 2 University of Pittsburgh, Pittsburgh, United States. 3 Georgia State University, Atlanta, Georgia, United States. 4 University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. 5 University of Pittsburgh Medical Center, Pittsburgh, PA, United States. 6 University of Pittsburgh, Pittsburgh, PA, United States. 7 Georgia State University, Atlanta, GA, United States. 8Georgia State University, Atlanta, Ga, United States.

Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade

Bai K, et al.
Head & Neck
August 2022
Authors and Affiliates
Ke Bai 1, Scott M Norberg 2, Cem Sievers 1, Tanya Meyer 3, Jay Friedman 1, Christian Hinrichs 4, Clint T Allen 1; 1 Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA. 2 Genitourinary Malignancies Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA. 3 Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA. 4 Rutgers Cancer Center, New Brunswick, New Jersey, USA.

Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy

Luoma AM, et al.
Cell
August 2022
Authors and Affiliates
Adrienne M Luoma 1, Shengbao Suo 2, Yifan Wang 3, Lauren Gunasti 4, Caroline B M Porter 5, Nancy Nabilsi 3, Jenny Tadros 3, Andrew P Ferretti 3, Sida Liao 3, Cagan Gurer 3, Yu-Hui Chen 6, Shana Criscitiello 4, Cora A Ricker 7, Danielle Dionne 5, Orit Rozenblatt-Rosen 5, Ravindra Uppaluri 8, Robert I Haddad 7, Orr Ashenberg 5, Aviv Regev 9, Eliezer M Van Allen 7, Gavin MacBeath 3, Jonathan D Schoenfeld 10, Kai W Wucherpfennig 11; 1 Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA. 2 Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA; Guangzhou Laboratory, Guangzhou, Guangdong 510005, China. Electronic address: suo_shengbao@gzlab.ac.cn. 3 TScan Therapeutics, Waltham, MA 02451, USA. 4 Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA 02115, USA. 5 Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. 6 Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 7 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 8 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA. 9 Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Howard Hughes Medical Institute and Koch Institute of Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. 10 Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Electronic address: jonathan_schoenfeld@dfci.harvard.edu. 11 Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA; Department of Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: kai_wucherpfennig@dfci.harvard.edu.

A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumors

Kumar N, et al.
August 2022
Authors and Affiliates
Namit Kumar 1, Simon Papillon-Cavanagh 1, Hao Tang 1, Shiliang Wang 1, Caitlyn Stromko 1, Ching-Ping Ho 1, Sonal Soni-Sheth 1, Steven Vasquez-Grinnell 1, Miranda L Broz 1, Daniel J Tenney 1, Michael J Wichroski 1, Alice M Walsh 1, Yanhua Hu 1, Joseph L Benci 1; 1 Bristol Myers Squibb: Research & Early Development, Princeton, New Jersey, USA.

Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers

Apavaloaei A, et al.
Cell Reports
August 2022
Authors and Affiliates
Anca Apavaloaei 1, Leslie Hesnard 2, Marie-Pierre Hardy 2, Basma Benabdallah 3, Gregory Ehx 2, Catherine Thériault 2, Jean-Philippe Laverdure 2, Chantal Durette 2, Joël Lanoix 2, Mathieu Courcelles 2, Nandita Noronha 1, Kapil Dev Chauhan 4, Sébastien Lemieux 5, Christian Beauséjour 6, Mick Bhatia 7, Pierre Thibault 8, Claude Perreault 9; 1 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; Department of Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada. 2 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada. 3 CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada. 4 Faculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada. 5 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada. 6 CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada; Department of Pharmacology and Physiology, University of Montreal, Montreal, QC H3T 1J4, Canada. 7 Faculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada. 8 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; Department of Chemistry, University of Montreal, Montreal, QC H3T 1J4, Canada. Electronic address: pierre.thibault@umontreal.ca. 9 Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada; Department of Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada. Electronic address: claude.perreault@umontreal.ca.

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Palmer CD, et al.
Nature Medicine
August 2022
Authors and Affiliates
Christine D Palmer 1, Amy R Rappaport 1, Matthew J Davis 1, Meghan G Hart 1, Ciaran D Scallan 1, Sue-Jean Hong 1, Leonid Gitlin 1, Lauren D Kraemer 1, Sonia Kounlavouth 1, Aaron Yang 1, Lindsey Smith 1, Desiree Schenk 1, Mojca Skoberne 1, Kiara Taquechel 1, Martina Marrali 1, Jason R Jaroslavsky 1, Charmaine N Nganje 1, Elizabeth Maloney 1, Rita Zhou 1, Daniel Navarro-Gomez 1, Adrienne C Greene 1, Gijsbert Grotenbreg 1, Renee Greer 1, Wade Blair 1, Minh Duc Cao 1, Shawn Chan 1, Kyounghwa Bae 1, Alexander I Spira 2, Sameek Roychowdhury 3, David P Carbone 3, Brian S Henick 4, Charles G Drake 4, Benjamin J Solomon 5, Daniel H Ahn 6, Amit Mahipal 7, Steve B Maron 8, Benny Johnson 9, Raphael Rousseau 1, Roman Yelensky 1, Chih-Yi Liao 10, Daniel V T Catenacci 10, Andrew Allen 1, Andrew R Ferguson 1, Karin Jooss 11; 1 Gritstone bio, Inc., Emeryville, CA, USA. 2 Virginia Cancer Specialists, Virginia Cancer Specialists, VA, Fairfax, USA. 3 The Ohio State University Medical Center, Columbus, OH, USA. 4 Columbia University Medical Center, New York, NY, USA. 5 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 6 Mayo Clinic, Phoenix, AZ, USA. 7 Mayo Clinic Cancer Center, Rochester, MN, USA. 8 Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9 The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 10 University of Chicago Comprehensive Cancer Center, Chicago, IL, USA. 11 Gritstone bio, Inc., Emeryville, CA, USA. kjooss@gritstone.com.

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer

Hoyos V, et al.
August 2022
Authors and Affiliates
Valentina Hoyos 1, Spyridoula Vasileiou 2, Manik Kuvalekar 2, Ayumi Watanabe 2, Ifigeneia Tzannou 2, Yovana Velazquez 2, Matthew French-Kim 2, Wingchi Leung 2, Suhasini Lulla 2, Catherine Robertson 2, Claudette Foreman 3, Tao Wang 3, Shaun Bulsara 3, Natalia Lapteva 2, Bambi Grilley 2, Matthew Ellis 3, Charles Kent Osborne 3, Angela Coscio 3, Julie Nangia 3, Helen E Heslop 2, Cliona M Rooney 2, Juan F Vera 2, Premal Lulla 2, Mothaffar Rimawi 3, Ann M Leen 2; 1 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, 1102 Bates Ave, Feigin Center 17th Floor. Houston, TX 77030, USA. 2 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA. 3 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.